Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036244 · ClinicalTrials.gov registry record · Phase 3
Synthetic Human Secretin in Children With Autism
A Phase 3 study, sponsored by Repligen Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00036244 is a Phase 3 study that has completed, run by Repligen Corporation.
The verdict
NCT00036244, a Phase 3 study, has completed, sponsored by Repligen Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.
Interventions
- DRUG RG1068 (Synthetic Human Secretin)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-04 |
| Est. Completion | 2004-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00036244
The ClinicalTrials.gov registry entry for NCT00036244 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Repligen Corporation, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RG1068 (Synthetic Human Secretin) is the first listed.
NCT00036244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00036244 about?
NCT00036244 is a clinical study titled "Synthetic Human Secretin in Children With Autism". The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.
What is the current status of trial NCT00036244?
This trial is currently completed. It is a Phase 3 study. The study started on 2002-04. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00036244?
The interventions under investigation include: RG1068 (Synthetic Human Secretin) (DRUG).
Who is sponsoring clinical trial NCT00036244?
This trial is sponsored by Repligen Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.